Hydroxyurea to inhibit human immunodeficiency virus-1 replication

Frank Romanelli, Claire Pomeroy, Kelly M. Smith

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Treatment of human immunodeficiency virus (HIV) infection continues to be a challenge. Drug regimens that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor are now the standard of care. These regimens require strict patient adherence and have numerous adverse effects at a high cost, so clinicians must continue to explore other therapeutic options. Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV. We conducted a critical review of the literature to examine the utility of hydroxyurea-based drug combinations.

Original languageEnglish
Pages (from-to)196-204
Number of pages9
Issue number2
StatePublished - 1999

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Hydroxyurea to inhibit human immunodeficiency virus-1 replication'. Together they form a unique fingerprint.

Cite this